On November 28, Chipscreen Biosciences' self-developed innovative drug, Epidaza® (Chidamide tablets), received approval for its first-line DLBCL treatment indication and was successfully added to the 2024 National Reimbursement Drug List (NRDL) (hereinafter referred to as the “new NRDL”). Bilessglu® (Chiglitazar Sodium tablets) has retained its type 2 diabetes indication at the current reimbursement price. The new NRDL will take effect on January 1, 2025. Epidaza®'s reimbursement coverage will now include: MYC/BCL2-positive, previously untreated diffuse large B-cell lymphoma (DLBCL), as well as relapsed or refractory peripheral T-cell lymphoma (PTCL) following at least one prior systemic chemotherapy. Bilessglu® will continue to be reimbursed for its existing indication: type 2 diabetes mellitus.